Home / 2019 / July / 08

Daily Archives: July 8, 2019

Batavia Biosciences receives $2.2 million follow-up grant from PATH to support new tools for polio eradication era

Leiden, 4 Jul 2019 – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus vaccines (nOPV). The project, which is funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from all types of polio.

Due to the tireless efforts of health organizations all over the world, the global eradication of polio is now within sight. The effort of PATH and partners has been to close one of the last loopholes for the spread of vaccine-derived poliovirus. The goal of the consortium is to develop novel, more attenuated and safer polio vaccine candidates against all three poliovirus serotypes to prevent person-to-person disease transmission, while not carrying the same risk of seeding new vaccine-derived polio cases as currently available oral polio vaccine (OPV). If found to be successful in trials, the nOPV candidates could be stockpiled and used as a safer response to possible future outbreaks after polio has been eradicated.

In January last year, Batavia Biosciences announced a partnership with PATH, where Batavia received a $4 million grant to produce master and working virus seeds for nOPV1, nOPV2, and nOPV3 vaccine candidates. Following successful results from this program, Batavia will now produce master and working virus seeds for the second nOPV1 and nOPV3 vaccine candidates in its GMP manufacturing facility in Leiden, the Netherlands. The novel candidate vaccine strains have been developed by the National Institute for Biological Standards and Control (NIBSC) in the United Kingdom, the U.S. Center for Disease Control and Prevention (CDC), and the University of California at San Francisco (UCSF). Batavia Biosciences contributes its extensive polio vaccine development experience and works closely with one of the world’s leading OPV vaccine manufacturers, Bio Farma, in Indonesia, under the nOPV consortium managed by PATH. It is of the intention that Bio Farma receives these virus seeds for ultimate production of nOPV1 and nOPV3 vaccines.

Chris Yallop, CSO of Batavia Biosciences, explains: “These novel oral polio vaccines have been developed with cutting edge technologies with the goal to deliver safer and efficacious vaccines that will hopefully protect people in case of vaccine-derived polio outbreaks in the future.”

Menzo Havenga, CEO of Batavia Biosciences, adds: “We are proud for this recognition and the opportunity to work together with PATH and partners to protect children around the world against this terrible disease.”

About Batavia Biosciences
Batavia Biosciences significantly contributes to ease human suffering from infectious diseases by improving the success rate in the translation of candidate medicines from discovery to the clinic. We offer our novel technologies and in-depth know-how in order to help our partners to complete preclinical phases in biopharmaceutical product development at higher speed, reduced costs and increased success. The company focuses on the early stages of product development including cell line generation, upstream process development (mammalian & microbial), purification development, product characterization and clinical manufacturing. Headquartered in Leiden, the Netherlands, with a subsidiary in Woburn, Massachusetts, and offices in Hong Kong, Batavia Biosciences is privileged to have strong strategic partners worldwide.

www.bataviabiosciences.com

Contact for editors
Chris Yallop, CSO

c.yallop@bataviabiosciences.com
+31889950600

Attachment

Lumina Networks Product Release Improves Service Reliability

Live in Tier-1 carrier network, release enables intent-based software defined infrastructure

SAN JOSE, Calif., July 08, 2019 (GLOBE NEWSWIRE) — Today, Lumina Networks introduced version 9.1 of the company’s Lumina Flow Manager, a key product in its SD-Core solution portfolio, to provide Communications Service Providers (CSPs) with advanced network traffic engineering and logical slicing as they move toward 5G. Deployed in a Tier-1 telecommunications network, the product improves reliability for disaggregated greenfield networks by supporting intent based slicing to help operators decongest their traditional MPLS cores and modernize the edge.

With this release Lumina Networks added key capabilities common in carrier grade MPLS networks to greenfield disaggregated whitebox networks – making them deployable in heterogeneous networks. Improving reliability and usability of whitebox resources, new features include automatic multicast optimization, LLDP monitoring, and fast failure detection and reroute, which provides dynamic configuration for MEF compliant E-line and E-Tree services.

  • Automated replication points & redundant ingress links with dynamic software control simplifies provisioning of e-tree services – Increases availability of the services while minimizing programming to support network disruptions.
  • BFD for OpenFlow Networks – Reduces anomaly identification time and promotes local-repair in green-field networks, thereby improving network intelligence and reliability.
  • P4 Whitebox switch Integration – Enables support for a wider range of switch hardware.
  • Provisioned Topology provides the framework for network slicing, allowing for the physical topologies to be represented via multiple logical topologies for path computation and operational processes.

Operating on Lumina’s OpenDaylight-based SDN Controller (Fluorine release), the application takes advantage of the latest community developments.

“As our customers continue to transform, controlling disparate network silos remains one of the biggest challenges as we head toward 5G,” says Andrew Coward, Lumina Networks, CEO. “We are pleased that this Lumina Flow Manager update has been proven in a live Tier-1 network – supporting 5X growth in switches and 15X growth in services – to help bridge the silos gap and improve efficiencies for transforming networks.”

Lumina Flow Manager has been tooled to help CSPs leverage open source solutions in heterogeneous environments to break free from vendor lock-in and deliver more customized, on-demand services. The company’s NetDev services team helps transforming companies moving to NetDevOps methodology. As the industry continues to advance through the transformation journey, Lumina Flow Manager will enable next generation networks like EVPN.

About Lumina Networks
Lumina Networks’ open source networking solutions simplify and automate heterogeneous networks. By combining engineering excellence, open source leadership and agile development methodology, Lumina Networks empowers Service Providers to reimagine their future without the risk of vendor lock-in. By unifying network architectures and enabling intent-based network functionality, Lumina Networks provides a more customer-centric approach to building and delivering on-demand, customizable services. Learn more about Lumina Networks at www.luminanetworks.com and @luminanetworks.

Media Contact:
Stephanie Owyoung, Lumina Networks
Director, Marketing
+1 (925) 719 – 4957
Sowyoung (at) luminanetworks.com

การเปิดตัวผลิตภัณฑ์ Lumina Networks เพื่อปรับปรุงความน่าเชื่อถือของบริการ

ในเครือข่ายผู้ให้บริการระดับ Tier-1 ได้มีการเปิดตัวช่วยให้โครงสร้างพื้นฐานซอฟต์แวร์ตามความต้องการ

ซานโฮเซ่, แคลิฟอร์เนีย, July 08, 2019 (GLOBE NEWSWIRE) — วันนี้ Lumina Networks ได้ทำการเปิดตัว Lumina Flow Manager เวอร์ชั่น 9.1 ของทางบริษัท ซึ่งเป็นผลิตภัณฑ์หลักในกลุ่มโซลูชัน SD-Core เพื่อให้บริการการสื่อสารแก่ผู้ให้บริการ (CSPs) ด้วยวิศวกรรมการรับส่งข้อมูลเครือข่ายขั้นสูง และการแบ่งส่วนเชิงตรรกะเมื่อเลื่อนไปสู่เครือข่าย 5G จะเริ่มนำไปใช้ในเครือข่ายโทรคมนาคม Tier-1 โดยผลิตภัณฑ์นี้ช่วยปรับปรุงความน่าเชื่อถือสำหรับเครือข่ายกรีนฟิลด์ที่แยกออกจากกัน โดยการสนับสนุนการแบ่งส่วนตามความต้องการเพื่อช่วยผู้ประกอบการลดแกน MPLS ดั้งเดิมและทำให้ทันสมัยยิ่งขึ้

ด้วยการเปิดตัวนี้ ทาง Lumina Networks ได้เพิ่มความสามารถที่สำคัญที่พบได้ทั่วไปในเครือข่าย MPLS ระดับผู้ให้บริการ ไปยังเครือข่ายไวท์บ็อกซ์แบบแยกส่วนกรีนฟิลด์ ซึ่งทำให้สามารถใช้งานได้ในเครือข่ายที่ต่างกัน การปรับปรุงความน่าเชื่อถือและการใช้งานทรัพยากรไวท์บ็อกซ์ ด้วยคุณสมบัติใหม่รวมถึงการเพิ่มประสิทธิภาพมัลติคาสต์อัตโนมัติ การตรวจสอบ LLDP และการตรวจจับความล้มเหลวอย่างรวดเร็วและเปลี่ยนเส้นทาง ซึ่งมีการกำหนดค่าแบบไดนามิกสำหรับบริการ E-line และ E-Tree

  • จุดจำลองแบบอัตโนมัติและลิงค์ทางเข้าแบบซ้ำพร้อมการควบคุมซอฟต์แวร์แบบไดนามิกจะช่วยลดความยุ่งยากในการจัดหาบริการ E-tree และเพิ่มความพร้อมใช้งานของบริการ ในขณะที่ลดการใช้งานโปรแกรมเพื่อรองรับการหยุดชะงักของเครือข่าย
  • BFD สำหรับเครือข่าย OpenFlow เพื่อลดเวลาการระบุความผิดปกติและส่งเสริมการซ่อมแซมในเครือข่ายท้องที่กรีนฟิลด์ ซึ่งจะช่วยเพิ่มความชาญฉลาดและความน่าเชื่อถือของเครือข่าย
  • การรวมสวิตช์ของ P4 ไวท์บ็อกซ์ เพื่อการเปิดใช้งานการรองรับฮาร์ดแวร์สวิตช์ที่หลากหลาย
  • การจัดสรรโทโพโลยีได้จัดเตรียมเฟรมเวิร์กสำหรับการแบ่งส่วนเครือข่าย ทำให้สามารถแสดงโทโพโลยีทางกายภาพผ่านโทโพโลยีทางตรรกะหลายๆ ตัวสำหรับการคำนวณเส้นทางและกระบวนการปฏิบัติงาน

การใช้งานระบบควบคุมการทำงานเครือข่าย SDN บน OpenDaylight ของ Lumina (Fluorine release) ซึ่งแอปพลิเคชันใช้ประโยชน์จากการพัฒนาเครือข่ายชุมชนล่าสุ

“ในขณะที่ลูกค้าของเรายังคงเปลี่ยนแปลง การควบคุมไซโลเครือข่ายที่แตกต่างกันยังคงเป็นหนึ่งในความท้าทายที่ยิ่งใหญ่ที่สุดเมื่อเรามุ่งหน้าไปยัง 5G” Andrew Coward CEO ของ Lumina Networks ได้กล่าวไว้ “เรามีความยินดีอย่างมากที่การอัพเดท Lumina Flow Manager นี้ได้รับการพิสูจน์แล้วในเครือข่าย Tier-1 ที่รองรับการเติบโต 5 เท่าของสวิทช์ และการบริการที่เติบโตกว่าเดิมอีก 15 เท่าเพื่อช่วยลดช่องว่างไซโล และปรับปรุงประสิทธิภาพสำหรับการเปลี่ยนของเครือข่าย”

Lumina Flow Manager ได้รับการออกแบบมาเพื่อช่วยให้ CSP ใช้ประโยชน์จากโซลูชันโอเพนซอร์สในสภาพแวดล้อมที่แตกต่างกันเพื่อแยกอิสระจากการติดสัญญาของผู้ขาย และมอบบริการแบบออนดีมานด์ที่กำหนดเองมากขึ้น ทีมบริการ NetDev ของบริษัท ช่วยเปลี่ยนให้บริษัทไปใช้วิธีการของ NetDevOps ในขณะที่อุตสาหกรรมยังคงก้าวหน้าไปตลอดเส้นทางการเปลี่ยนแปลง Lumina Flow Manager จะเป็นเครือข่ายเจนเนอเรชันถัดไปเหมือนกับ EVPN

เกี่ยวกับ Lumina Networks 
โซลูชันระบบเครือข่ายโอเพนซอร์สของ Lumina Networks ช่วยให้เครือข่ายต่างกันเป็นไปอย่างง่ายดายและอัตโนมัติ ด้วยการผสานความเป็นเลิศทางวิศวกรรม ความเป็นผู้นำแบบโอเพนซอร์ส และวิธีการพัฒนาที่รวดเร็วทำให้ Lumina Networks ช่วยให้ผู้ให้บริการสามารถกำหนดอนาคตของพวกเขาได้โดยไม่ต้องเสี่ยงต่อสัญญาผูกมัดของผู้ขาย ด้วยการรวมสถาปัตยกรรมเครือข่ายและการเปิดใช้งานฟังก์ชั่นเครือข่ายตามความต้องการ Lumina Networks มอบวิธีการที่ให้ลูกค้าเป็นศูนย์กลางในการสร้างและส่งมอบบริการแบบออนดีมานด์ที่ปรับแต่งได้ เรียนรู้เพิ่มเติมเกี่ยวกับ Lumina Networks ได้ที่ www.luminanetworks.com และ @luminanetworks.

ติดต่อ:
Stephanie Owyoung, Lumina Networks
ผู้อำนวยการฝ่ายการตลาด
+1 (925) 719 – 4957
Sowyoung (at) luminanetworks.com

Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025

Collaboration prioritizes scientific innovation and social change to one day eliminate lung cancer as a cause of death

LONDON, July 08, 2019 (GLOBE NEWSWIRE) — Today, the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca announced the Lung Ambition Alliance, a new partnership with a bold ambition to eliminate lung cancer as a cause of death. The first goal of the Alliance will be to double five-year survival for patients with lung cancer by 2025.

Every 18 seconds, a life is lost to lung cancer.1 In 2018 alone, approximately 1.8 million people died from the disease.1 Forty percent of patients are diagnosed when the cancer has already spread beyond the lung and their prognosis has worsened.2 Currently, only one in five lung cancer patients are alive five years after diagnosis.3

Jesme Fox, Secretary for GLCC, said: “The Lung Ambition Alliance has been created at a pivotal time for lung cancer. Scientific advances are enabling new possibilities to transform diagnosis, treatment and the management of the disease. Yet barriers remain to improving and accelerating care. As members of the lung cancer community, we have a responsibility to come together with urgency to advocate for and advance the best solutions for patients.”

The Alliance represents a broad range of complementary expertise, including research and education (IASLC), diagnostics (Guardant Health), patient advocacy (GLCC), and medicines research and development (AstraZeneca).

The founding partners have identified three priorities: increasing screening and early diagnosis, delivering innovative medicine and improving the quality of care for people with lung cancer. Initial projects being accelerated through the Alliance include:

  1. The Early Lung Imaging Confederation (ELIC) is a new, cloud-based worldwide screening database designed to accelerate improvements in the multidisciplinary detection and management of early-stage lung cancer. The project capitalizes on growing evidence that CT screening can lead to reduced mortality.4 This collection of images and data can be used to build better risk models, as well as analysis and detection tools, while serving as a global standard for data quality. In a future phase, artificial intelligence (AI) may be applied to further improve the reliability of clinical decision-support with CT screening. The Alliance will contribute to building out the image bank for this IASLC-owned project, first piloted in late 2018, and will assist in measuring patient outcomes to be assessed at various points in the patient journey (including initial scan, initial treatment, and follow up).

Giorgio Scagliotti, President of IASLC said: “Effective screening is key to finding and diagnosing lung cancer and other thoracic malignancies early, which can translate to more options and longer survival. Yet screening is underutilized around the world for several reasons. The application of quantitative imaging approaches like ELIC could improve the accuracy and the efficiency of lung cancer screening. Our platform is poised to become an important global resource for lung cancer researchers and care teams looking to expand their knowledge. The Lung Ambition Alliance is providing the focus, expertise, and resources needed to dramatically accelerate the expansion of our data catalogue.”

  1. The Major Pathologic Response Project is a collection of clinical trial data and research that can be used to validate surrogate endpoints and identify predictive biomarkers, which may enable better targeting of tumor characteristics. Its aims to accelerate development of the next generation of targeted treatments and drive the shift to earlier intervention when there is greater potential for a cure.5 The Alliance is assisting in the pooling of data from cooperative groups and across pharmaceutical industry trials, which can be used with health authorities around the world when discussing pivotal trial data.

AmirAli Talasaz, President and Chief Operating Officer, Guardant Health said: “Precision medicine is improving prognosis for some lung cancer patients and delivering better clinical outcomes. We believe precision medicine approaches can be even more effective when utilized earlier in the course of the disease, or immediately upon detection of relapse. The Major Pathologic Response Project will help accelerate development of potentially curative treatment options, with the identification of surrogate endpoints that can be used to quicken clinical trials and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor prognosis, allow routine assessment of therapeutic response, and promote ongoing monitoring of cancer remission.”

  1. Initiatives in Lung Cancer Care (ILC2) is an open call anticipated to launch in late 2019, inviting local patient organizations around the world to develop and submit pilot projects that can potentially transform patient care and improve survival at the local level. It aims to help the local lung cancer community benefit from multidisciplinary best practices, educate patients about their options and provide quality-of-life support to patients throughout and following treatment. A Lung Ambition Alliance committee will evaluate and select submissions that have met the selection criteria for funding.

Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, AstraZeneca, said: “Lung cancer is a highly personal disease, and care approaches can vary widely around the world. In order to reach our survival goal, we must encourage initiatives that address barriers at the country level and increase screening and early diagnosis, aid the development of innovative medicine and improve quality care. By joining together with partners who have broad global networks and distinct but complementary areas of focus in lung cancer, we are better positioned to address issues those patients face.”

The Alliance will sponsor an international survey, led by Ipsos MORI, to identify local barriers that need priority focus. Results, expected in the fall of 2019, will be used to further refine and shape the priorities of the Lung Ambition Alliance. Information about the survey, and how the community can share their perspectives, can be found at LungAmbitionAlliance.org.

About the Lung Ambition Alliance

The Lung Ambition Alliance is a flagship partnership of diverse organizations united in the quest to eliminate lung cancer as a cause of death. The Alliance aims to accelerate progress and bring meaningful change for lung cancer patients by amplifying the expertise of each partner and prioritizing meaningful projects with potential to further its goal. The founding partners – the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca – will explore and overcome barriers to screening and early diagnosis, the development of innovative medicine and quality care, and pursue an ambitious vision for the future in lung cancer that starts with doubling five-year survival by 2025.

For more information, visit www.lungambitionalliance.org.

About the Founding Partners

  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies, with a global network of more than 6,500 lung cancer specialists across all disciplines in over 100 countries.
  • The Global Lung Cancer Coalition is the international voice of lung cancer patients and committed to patient advocacy.
  • Guardant Health is an innovative diagnostics company with a vision to enable earlier detection through access to molecular information in the blood.
  • AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines.

CONTACTS:

Jennifer Corrigan
BursonRx
Jennifer.Corrigan@bursonrx.com
+1-347-366-1444

Emma Barrow
GCI Health
Emma.Barrow@gcihealth.com
+44-207-300-6114

Accelerating Advances for People with Lung Cancer.

References
______________________

1 World Health Organization. International Agency for Research on Cancer. Fact Sheet – Lung Cancer. Available at http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed May 2019
2 EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
3 Cancer.Net. Lung Cancer – Non-Small Cell – Statistics. Available at www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed May 2019
4 IASLC. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at https://www.iaslc.org/news/iaslc-successfully-pilots-early-lung-imaging-confederation-project-0. Accessed May 2019
5 IASLC. IASLC Pathology Committee. Available at https://www.iaslc.org/research-education/iaslc-pathology-committee. Accessed May 2019

Wolters Kluwer launches new regulatory software, first on cloud

KUALA LUMPUR, Wolters Kluwer’s Finance, Risk and Reporting (FRR) business has launched a software-as-a-service (SaaS) Regulatory Reporting solution.

The solution marks the first time that the company’s OneSumX regulatory software has been made available on the cloud, providing predictability of cost and lower total cost of ownership.

Wolters Kluwer FRR is also unveiling a major upgrade to its OneSumX Regulatory Engine, which will be rolled out for on-premise installations of OneSumX for Regulatory Reporting.

In a statement, the company said it would be immediately available in the new SaaS offering for clients across Europe and Asia Pacific.

The new Regulatory Engine will be characterised by its enhanced performance and better user- experience, in terms of speed, automation and scalability.

The upgraded platform enables clients to capture source data into regulatory defined reports and run validation, adjustments and auditing before submitting data to regulators.

More details on https://wolterskluwer.com/

Source: BERNAMA (News Agency)

HSBC Malaysia launches supply chain platform

KUALA LUMPUR, HSBC Malaysia has launched HSBC Supply Chain Finance (HSCF) platform, an electronic platform that enables customers to upload approved invoices catering to basic file upload and host to host requirements.

In a statement today, it said via HSCF, customers could transmit approved invoices and payment files to the bank at any time and anywhere, thus, allowing for accelerated early payments to suppliers.

Beyond speed, the platform provides suppliers with visibility into the status of buyer-approved invoices from HSBC, even if the supplier is not a direct HSBC customer, it said.

The bank said HSCF was the latest addition to its suite of digital trade capabilities, which would help support the nation’s aspiration for Malaysian small and medium-sized enterprises (SMEs) to make up 41 per cent of the country’s gross domestic product by 2020.

HSBC Malaysia country head of commercial banking Andrew Sill said HSCF platform demonstrated the bank’s commitment to meet customers’ demands in its ever-evolving digital era where convenience, speed and flexibility were the new norms.

We are always looking for new ways to leverage technology to provide our customers with digital products and services that are simple, convenient and secure, he said.

Source: BERNAMA (News Agency)

TDM unit secures contract to supply 107,500 tonnes of CPO

KUALA LUMPUR, TDM Bhd has secured a deal to sell 107,500 metric tonnes (MT) of crude palm oil (CPO) to Ikhasas CPO Sdn Bhd over 43 months.

Its wholly owned subsidiary, TDM Plantation Sdn Bhd, today entered into an agreement with Ikhasas for the supply of 2,500 MT of CPO and/or Roundtable on Sustainable Palm Oil (RSPO)-certified CPO products per month.

“An upfront payment of RM189 million will be paid in three tranches at the beginning of the supply period, subject to deduction for the provision of a sinking fund as required under the agreement.

“The value with respect to the products delivered will be deducted from such upfront payment made to the seller,” TDM said in a filing with Bursa Malaysia today.

The transaction would enable the group to partly secure placement of its future CPO and certified CPO as well as improve liquidity through the repayment of a portion of its borrowings that were due in the near term, it added.

Source: BERNAMA (News Agency)